Big strides in solving big human health problems! Careers @ Myeloid
Retro-T Gene Editing
// KEY PLATFORM CHARACTERISTICS
Next-Gen Delivery
Myeloid is powered by our team of talented, driven scientists and biotech industry experts whose expertise spans oncology, immunology, mRNA biology, cell therapy, synthetic biology, and gene delivery.
Gene delivery and writing using mRNA
Harnessing the frequent migration of myeloid cells from the blood into solid tumors as well as sites of inflammation
Stable mRNA expression
Directing phagocytic properties of myeloid cells, including the capability to recognize and engulf cancer cells
Prime medicine collaboration
Empowering myeloid cells to produce anti-tumor agents and modify the tumor microenvironment
Field rights retained
Bridging innate and adaptive immunity, to elicit a broad anti-tumor immune response with tumor-specific T cells
// FIRST POINT
Lorem Ipsum 1
Our proprietary RNA-based, retrotransposon mediated gene-insertion technology, (RetroT™), has applications across gene editing and delivery. Retrotransposons are genetic elements that have the capability of replicating through reverse transcription of an RNA transposition intermediate. They contribute to structural changes and more importantly to gene regulation.
// SECOND POINT
Lorem Ipsum 2
Our retrotransposon-based approach relies on mRNA to deliver genetic sequences and integration enzymes in a single mRNA strand. This breakthrough technology offers the potential to deliver gene-sized pieces of DNA into the genome, which are larger than currently possible with existing gene editing technologies. As a result, it holds the potential to significantly expand the type and scope of genetic errors that can be reversed in situ.
// THIRD POINT
Lorem Ipsum 3
In March 2022, we announced that we entered into an exclusive research collaboration and option agreement with Prime Medicine to develop and accelerate RetroT. As part of the deal, Myeloid received a $45M upfront payment and the company is eligible for significant future milestones.